

ASX Announcement

Addendum to Notice of Extraordinary General Meeting

Sydney, Australia, 27 May 2025: Imugene Limited (ASX:IMU) (Imugene or the **Company**) gives notice to shareholders of amendments to the Notice of Extraordinary General Meeting released today to the ASX (**Notice**) and accompanying explanatory memorandum (**Explanatory Memorandum**) for its upcoming Extraordinary General Meeting of the Company to be held at 9.00am (Sydney time) on 26 June 2025 at McCullough Robertson, Level 32, 25 Martin Place, Sydney NSW 2000. The meeting will also be conducted online by Zoom conference.

This Addendum to the Notice of Extraordinary General Meeting (**Addendum**) is supplemental to the original Notice and Explanatory Memorandum and should be read together with the Notice and Explanatory Memorandum. To the extent of any inconsistency, this Addendum will prevail over the original Notice and Explanatory Memorandum.

Definitions in the Notice have the same meaning in this Addendum unless otherwise updated in this Addendum.

The changes to the Notice as outlined in this Addendum are as follows:

- Page 5 of the Notice – Shareholders with any queries, including how to cast your votes, should contact the Company’s Share registry on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) during business hours.
- Page 7 of the Explanatory Memorandum Resolution 1 – For security code IMUAAK, the correct pre-consolidation exercise price is \$0.24 and the correct post-consolidation exercise price is \$8.16 .

Important Notice

This addendum should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

By order of the Board.



For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and



resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Company Secretary Imugene Limited.